Un estudio para probar diferentes dosis de BI 1810631 en personas con diferentes tipos de cáncer avanzado (tumores sólidos con cambios en el gen HER2)
Un ensayo abierto, fase I de aumento de dosis, con confirmación y expansión de dosis, de BI 1810631 como monoterapia en pacientes con tumores sólidos avanzados o metastásicos con aberraciones de HER2
The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful.
The second part is open to people with non-small cell lung cancer with a specific mutation in the HER2 gene.
The purpose of the first study part is to find the highest dose of a medicine called zongertinib the participants can tolerate. Once this dose is found, it will be used in the second study part to test whether zongertinib can make tumours shrink.
In this study, zongertinib is given to people for the first time. Participants take zongertinib as tablets once a day or twice a day.
The participants are in the study for as long as they benefit from and can tolerate treatment.
Study doctors regularly check the participants' health and monitor the tumours. The doctors also take note of any unwanted effects that could have been caused by zongertinib.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Additional US locations available on demand. Please contact for options.
- Número de teléfono: 1-800-243-0127
Copia de seguridad de contactos de estudio
- Nombre: Boehringer Ingelheim
- Número de teléfono: 1-800-243-0127
- Correo electrónico: clintriage.rdg@boehringer-ingelheim.com
Ubicaciones de estudio
-
-
-
Augsburg, Alemania, 86156
- Terminado
- Universitätsklinikum Augsburg
-
Cologne, Alemania, 50937
- Reclutamiento
- Universitätsklinikum Köln (AöR)
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 08007234742
- Correo electrónico: deutschland@bitrialsupport.com
-
Dresden, Alemania, 01307
- Reclutamiento
- Technische Universität Dresden
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 08007234742
- Correo electrónico: deutschland@bitrialsupport.com
-
Giessen, Alemania, 35392
- Reclutamiento
- Justus-Liebig Universität Gießen
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 08007234742
- Correo electrónico: deutschland@bitrialsupport.com
-
Oldenburg, Alemania, 26121
- Reclutamiento
- Pius-Hospital, Oldenburg
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 08007234742
- Correo electrónico: deutschland@bitrialsupport.com
-
-
-
-
New South Wales
-
Macquarie Park, New South Wales, Australia, 2109
- Terminado
- Macquarie University
-
-
-
-
-
Linz, Austria, 4020
- Terminado
- Ordensklinikum Linz GmbH
-
-
-
-
-
Anderlecht/Brussels-Capital, Bélgica, 1070
- Activo, no reclutando
- Brussels - HOSP Jules Bordet
-
-
-
-
-
Chungju, Corea del Sur, 28644
- Reclutamiento
- Chungbuk National University Hospital
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 0808802084
- Correo electrónico: namhan@bitrialsupport.com
-
Seongnam, Corea del Sur, 13620
- Reclutamiento
- Seoul National University Bundang Hospital
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 0808802084
- Correo electrónico: namhan@bitrialsupport.com
-
Seoul, Corea del Sur, 05505
- Reclutamiento
- Asan Medical Center
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 0808802084
- Correo electrónico: namhan@bitrialsupport.com
-
Seoul, Corea del Sur, 06351
- Reclutamiento
- Samsung Medical Center
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 0808802084
- Correo electrónico: namhan@bitrialsupport.com
-
Seoul, Corea del Sur, 03722
- Activo, no reclutando
- Severance Hospital
-
-
-
-
-
Barcelona, España, 08035
- Activo, no reclutando
- Hospital Universitari Vall d'Hebron
-
L'Hospitalet de Llobregat, España, 08907
- Activo, no reclutando
- Hospital Duran i Reynals
-
Madrid, España, 28041
- Activo, no reclutando
- Hospital Universitario 12 de Octubre
-
Madrid, España, 28007
- Terminado
- Hospital General Universitario Gregorio Marañón
-
Málaga, España, 29010
- Activo, no reclutando
- Hospital Universitario Virgen de la Victoria
-
Valencia, España, 46010
- Activo, no reclutando
- Hospital Clinico Universitario de Valencia
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- Reclutamiento
- University of Alabama at Birmingham
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 833-602-2368
- Correo electrónico: unitedstates@bitrialsupport.com
-
-
California
-
Beverly Hills, California, Estados Unidos, 90212
- Terminado
- Precision NextGen Oncology
-
Duarte, California, Estados Unidos, 91010
- Reclutamiento
- City of Hope-Duarte-56419
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 833-602-2368
- Correo electrónico: unitedstates@bitrialsupport.com
-
Huntington Beach, California, Estados Unidos, 92648
- Terminado
- City of Hope - Seacliff
-
Irvine, California, Estados Unidos, 92618
- Terminado
- City of Hope-Irvine-69674
-
Los Angeles, California, Estados Unidos, 90067
- Reclutamiento
- Valkyrie Clinical Trials
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 833-602-2368
- Correo electrónico: unitedstates@bitrialsupport.com
-
Orange, California, Estados Unidos, 92868
- Reclutamiento
- University of California Irvine
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 833-602-2368
- Correo electrónico: unitedstates@bitrialsupport.com
-
Sacramento, California, Estados Unidos, 95817
- Reclutamiento
- University of California Davis
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 833-602-2368
- Correo electrónico: unitedstates@bitrialsupport.com
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20007
- Reclutamiento
- Georgetown University
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 833-602-2368
- Correo electrónico: unitedstates@bitrialsupport.com
-
-
Florida
-
Fort Lauderdale, Florida, Estados Unidos, 33308
- Reclutamiento
- Holy Cross Hospital-Fort Lauderdale-57892
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 833-602-2368
- Correo electrónico: unitedstates@bitrialsupport.com
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Reclutamiento
- Winship Cancer Institute
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 833-602-2368
- Correo electrónico: unitedstates@bitrialsupport.com
-
-
Hawaii
-
Honolulu, Hawaii, Estados Unidos, 96813
- Reclutamiento
- Hawaii Cancer Care - Honolulu
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 833-602-2368
- Correo electrónico: unitedstates@bitrialsupport.com
-
-
New York
-
New York, New York, Estados Unidos, 10016
- Reclutamiento
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 833-602-2368
- Correo electrónico: unitedstates@bitrialsupport.com
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27710
- Reclutamiento
- Duke University Medical Center
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 833-602-2368
- Correo electrónico: unitedstates@bitrialsupport.com
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Reclutamiento
- Cleveland Clinic
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 833-602-2368
- Correo electrónico: unitedstates@bitrialsupport.com
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Reclutamiento
- Sarah Cannon Research Institute-Nashville-48456
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 833-602-2368
- Correo electrónico: unitedstates@bitrialsupport.com
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75230
- Reclutamiento
- Mary Crowley Cancer Research Center
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 833-602-2368
- Correo electrónico: unitedstates@bitrialsupport.com
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- The University of Texas MD Anderson Cancer Center
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 833-602-2368
- Correo electrónico: unitedstates@bitrialsupport.com
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Reclutamiento
- Virginia Cancer Specialists, PC
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 833-602-2368
- Correo electrónico: unitedstates@bitrialsupport.com
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109
- Reclutamiento
- Fred Hutchinson Cancer Research Center
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 833-602-2368
- Correo electrónico: unitedstates@bitrialsupport.com
-
-
-
-
-
Bron, Francia, 69677
- Activo, no reclutando
- Hopital Louis Pradel
-
Lyon, Francia, 69373
- Activo, no reclutando
- CTR Leon Berard
-
Marseille, Francia, 13385
- Activo, no reclutando
- HOP Timone
-
Paris, Francia, 75005
- Activo, no reclutando
- INS Curie
-
Rennes, Francia, 35000
- Activo, no reclutando
- HOP Pontchaillou
-
Villejuif, Francia, 94805
- Activo, no reclutando
- Institut Gustave Roussy
-
-
-
-
-
Hong Kong, Hong Kong
- Activo, no reclutando
- Queen Mary Hospital
-
Hong Kong, Hong Kong, 999077
- Activo, no reclutando
- Prince of Wales Hospital-Hong Kong-20715
-
-
-
-
-
Haifa, Israel, 3109601
- Terminado
- Rambam Medical Center
-
Kfar Saba, Israel, 44281
- Terminado
- Meir Medical Center
-
Tel Aviv, Israel, 6423906
- Activo, no reclutando
- Sourasky Medical Center
-
Tel HaShomer, Israel, 52621
- Terminado
- The Chaim Sheba Medical Center Tel HaShomer
-
-
-
-
-
Candiolo (TO), Italia, 10060
- Terminado
- Istituto Di Candiolo
-
Naples, Italia, 80131
- Terminado
- Istituto Nazionale IRCCS Tumori Fondazione Pascale
-
Parma, Italia, 43100
- Terminado
- Azienda Ospedaliera Unversitaria di Parma
-
-
-
-
-
Chiba, Kashiwa, Japón, 277-8577
- Reclutamiento
- National Cancer Center Hospital East
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 05050508862
- Correo electrónico: nippon@bitrialsupport.com
-
Ehime, Matsuyama, Japón, 791-0280
- Reclutamiento
- Shikoku Cancer Center
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 05050508862
- Correo electrónico: nippon@bitrialsupport.com
-
Hiroshima, Hiroshima, Japón, 734-8551
- Reclutamiento
- Hiroshima University Hospital
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 05050508862
- Correo electrónico: nippon@bitrialsupport.com
-
Osaka, Osaka, Japón, 541-8567
- Reclutamiento
- Osaka International Cancer Institute
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 05050508862
- Correo electrónico: nippon@bitrialsupport.com
-
Osaka, Sakai, Japón, 590-0197
- Reclutamiento
- Kindai University Hospital
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 05050508862
- Correo electrónico: nippon@bitrialsupport.com
-
Shizuoka, Hamamatsu, Japón, 431-3192
- Reclutamiento
- Hamamatsu University Hospital
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 05050508862
- Correo electrónico: nippon@bitrialsupport.com
-
Tokyo, Chuo-ku, Japón, 104-0045
- Reclutamiento
- National Cancer Center Hospital
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 05050508862
- Correo electrónico: nippon@bitrialsupport.com
-
-
-
-
-
Amsterdam, Países Bajos, 1066 CX
- Reclutamiento
- Nederlands Kanker Instituut
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 08000204613
- Correo electrónico: nederland@bitrialsupport.com
-
Leiden, Países Bajos, 2333 ZA
- Activo, no reclutando
- Leids Universitair Medisch Centrum (LUMC)
-
-
-
-
-
Beijing, Porcelana, 100036
- Terminado
- Beijing Cancer Hospital
-
Changchun, Porcelana, 130021
- Activo, no reclutando
- The First Hospital of Jilin University
-
Changchun, Porcelana, 130012
- Terminado
- Jilin Province Cancer Hospital
-
Fuzhou, Porcelana, 350014
- Activo, no reclutando
- Fujian Cancer Hospital
-
Guangzhou, Porcelana, 510080
- Activo, no reclutando
- Guangdong Provincial People's Hospital
-
Hangzhou, Porcelana, 310022
- Activo, no reclutando
- Zhejiang Cancer Hospital
-
Hangzhou, Porcelana, 310003
- Activo, no reclutando
- The First Affiliated Hospital, Zhejiang University
-
Harbin, Porcelana, 150081
- Activo, no reclutando
- Harbin Medical University Cancer Hospital
-
Nanning, Porcelana, 530021
- Terminado
- The Affiliated Cancer Hospital, Guangxi Medical University
-
Shanghai, Porcelana, 200030
- Terminado
- Shanghai Chest Hospital
-
Wuhan, Porcelana, 430030
- Activo, no reclutando
- Tongji Hospital Affiliated Tongji Medical College Huazhong University of S & T
-
Wuhan, Porcelana, 430022
- Activo, no reclutando
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
-
Xiamen, Porcelana, 361003
- Terminado
- First Affiliated Hospital of Xiamen University
-
Zhengzhou, Porcelana, 450052
- Activo, no reclutando
- The First Affiliated Hospital of Zhengzhou University
-
Zhengzhou, Porcelana, 450008
- Activo, no reclutando
- Henan Cancer Hospital
-
-
-
-
-
Porto, Portugal, 4100-180
- Terminado
- Hospital CUF Porto
-
-
-
-
-
London, Reino Unido, SW3 6JJ
- Activo, no reclutando
- The Royal Marsden Hospital, Chelsea
-
London, Reino Unido, W12 0HS
- Activo, no reclutando
- Hammersmith Hospital
-
Sutton, Reino Unido, SM2 5PT
- Activo, no reclutando
- The Royal Marsden Hospital, Sutton
-
-
-
-
-
Singapore, Singapur, 169610
- Reclutamiento
- National Cancer Centre Singapore
-
Contacto:
- Boehringer Ingelheim
- Número de teléfono: 8001207344
- Correo electrónico: singapore@bitrialsupport.com
-
Singapore, Singapur, 119228
- Terminado
- National University Hospital-Singapore-22806
-
-
-
-
-
Stockholm, Suecia, 171 76
- Terminado
- Karolinska Universitetssjukhuset Solna
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Histologically or cytologically confirmed diagnosis of an advanced, unresectable and/or metastatic non-haematologic malignancy. Patient must show presence of at least one measurable lesion according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.
-
Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2 (ECOG=2 only for Cohorts 6, 7 and 9) .
-
Availability and patient willingness to provide a sample of tumour for confirmation of the patient´s Human epidermal growth factor receptor 2 (HER2) status. This sample can be archival material obtained at any time prior to study enrollment.
-
Patient willing and able to comply with the protocol requirements for tumour biopsies (biopsies from brain metastases are not allowed).
-
Adequate organ function defined as all of the following:
- Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (≥ 1.5 x 10^3/μL) (≥ 1500/mm^3); haemoglobin ≥ 9.0 g/dL (≥ 90 g/L) (≥ 5.6 mmol/L); platelets ≥ 100 x 10^9/L (100 x 10^3/μL) (100 x 10^3/mm3) without the use of hematopoietic growth factors within 4 weeks of start of trial medication.
- Total bilirubin ≤ 1.5 times the upper limit of normal (ULN), except for patients with Gilbert's syndrome: total bilirubin ≤ 3 x ULN or direct bilirubin ≤ 1.5 x ULN.
- Estimated Glomerular Filtration Rate (eGFR) ≥ 50 mL/min - calculated using Chronic Kidney Disease Epidemiology (CKD-EPI) formula (≥ 30 mL/min/1.73m² for cohorts 6, 8, and 9).
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN if no demonstrable liver metastases, or otherwise ≤ 5 x ULN if transaminase elevation is attributable to liver metastases.
- Alkaline Phosphatase < 5 x ULN.
-
Recovered from any previous therapy-related toxicity to ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at start of treatment (except for alopecia, stable sensory neuropathy and hypothyroidism (patients on thyroid replacement therapy) which must be ≤ CTCAE Grade 2)
-
Life expectancy of at least 12 weeks at the start of treatment in the opinion of the investigator.
-
At least 18 years of age at the time of consent or over the legal age of consent in countries where that is greater than 18 years.
-
Signed and dated written informed consent in accordance with International Council on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
-
Male or female patients. Women of childbearing potential (WOCBP) and men who are able to father a child must be ready and able to use highly effective methods of birth control per International Council on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly.
Additional inclusion criteria for Phase Ia
- Patients with a documented diagnosis of HER2 aberration: overexpression OR gene amplification OR non-synonymous somatic mutation OR gene rearrangement involving HER2 or Neuregulin 1 (NRG1)
- Patient who has failed conventional treatment or for whom no therapy of proven efficacy exists or who is not eligible for established treatment options. Patient must have exhausted, or not be a suitable candidate for, available treatment options known to prolong survival for their disease
Additional inclusion criteria for Phase Ib - Cohort 1 only
- Non-squamous non-small cell lung cancer (NSCLC) patients with documented human epidermal growth factor receptor 2 (HER2) mutation in the tyrosine kinase domain (TKD) as per local lab results.
- Patient who had received, in the advanced/metastatic setting, at least one line of systemic therapy. Patients with non-squamous NSCLC harboring additionally genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy.
Additional inclusion criteria for Phase Ib - Cohort 2 only
- Non-squamous NSCLC patient with a documented HER2 mutation in the tyrosine kinase domain (TKD) as per local lab results.
- Treatment naïve for non-squamous NSCLC.
Additional inclusion criteria for Phase Ib - Cohort 3 only
- NSCLC Patient with a documented HER2 mutation outside of the tyrosine kinase domain (TKD) as per local lab results or squamous NSCLC patient with mutation in the TKD as per local lab results. After implementation of CTP v8, only non-squamous NSCLC patients with a documented activating HER2 mutation outside of the tyrosine kinase domain (TKD) as per local lab results.
- Patient who had received, in the advanced/metastatic setting, at least one line of systemic therapy. Patients with NSCLC harboring additionally genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy. After implementation of CTP v8, patients who had received, in the advanced/metastatic setting, at least one line of systemic therapy OR patients who are treatment naïve for non-squamous NSCLC (no prior systemic therapy, immunotherapy or targeted therapy for stage IIIB or IV adenocarcinoma).
Additional inclusion criteria for Phase Ib - Cohort 4 only
- NSCLC patients with documented HER2 mutation in the TKD as per local lab results.
- NSCLC patients who are either treatment naïve or who had received any prior line of treatment, in the advanced/metastatic setting. Patients with NSCLC harboring additional genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy.
- Patient with active brain metastases who are not eligible for immediate local therapy, as per investigator evaluation.
Additional inclusion criteria for Phase Ib - Cohort 5 only
- Non-squamous NSCLC patients with documented HER2 mutation in the TKD as per local lab results.
- Patient should have received, in the advanced/metastatic setting, at least one line of systemic therapy that includes a platinum-based combination chemotherapy and should have been treated with previous HER2 directed antibody-drug conjugates (ADC) in the same advanced/metastatic setting and developed disease progression recurrence during or after completing this therapy. Patients with NSCLC harboring additional genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy.
Additional inclusion criteria for Phase Ib - Cohort 6 only
- Non-squamous NSCLC patient with documented HER2 mutation in the TKD as per local lab results.
- Patient who had received, in the advanced/metastatic setting, at least one line of systemic therapy.
- Patient without active brain metastases or patient with active brain metastases who are not eligible for immediate local therapy, as per investigator evaluation.
- Patient who is not eligible for any other recruiting cohort.
Additional inclusion criteria for Phase Ib - Cohort 7 only
- Non-squamous NSCLC patient with documented HER2 mutation in the TKD as per local lab results.
- Patient who had received, in the advanced/metastatic setting, at least one line of systemic therapy.
- Patient without active brain metastases or patient with active brain metastases who are not eligible for immediate local therapy, as per investigator evaluation.
- Patient who is not eligible for any other recruiting cohort.
Additional inclusion criteria for Phase Ib - Cohort 8 only
- Treatment naïve for NSCLC
- NSCLC (adenocarcinoma or squamous) patient with documented HER2 mutation in the tyrosine kinase domain (TKD) or non-squamous NSCLC with a documented HER2 mutation in the non tyrosine kinase domain (non TKD) as per local lab results
Additional inclusion criteria for Phase Ib - Cohort 9 only
- Non-squamous NSCLC patient with documented HER2 mutation in the TKD as per local lab results.
- Patient who had received, in the advanced/metastatic setting, at least one line of systemic therapy. Patients with NSCLC harboring additionally genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy.
Further inclusion criteria apply.
Exclusion Criteria:
-
Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to first trial treatment or planned within 6 months after screening
-
Previous or concomitant malignancies other than the one treated in this trial within the last 2 years, except:
- effectively treated non-melanoma skin cancers
- effectively treated carcinoma in situ of the cervix
- effectively treated ductal carcinoma in situ
- other effectively treated malignancy that is considered cured by local treatment.
-
Treatment with a systemic anti-cancer therapy or investigational drug within 21 days or 5 half-lives (whichever is shorter) of the first treatment with the study medication
-
Patients who must or wish to continue the intake of restricted medication or any drug considered likely to interfere with the safe conduct of the trial
-
Previous treatment with zongertinib.
-
Radiotherapy within 2 weeks prior to first study treatment, except palliative radiotherapy to regions other than the chest, which is allowed up to 1 week prior to first study treatment.
Further exclusion criteria apply.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Fase Ib - Parte de expansión de dosis: Cohorte 1
|
zongertinib
Otros nombres:
|
|
Experimental: Fase Ib - Parte de expansión de dosis: Cohorte 2
|
zongertinib
Otros nombres:
|
|
Experimental: Fase Ib - Parte de expansión de dosis: Cohorte 3
|
zongertinib
Otros nombres:
|
|
Experimental: Fase Ib - Parte de expansión de dosis: Cohorte 4
|
zongertinib
Otros nombres:
|
|
Experimental: Fase Ib - Parte de expansión de dosis: Cohorte 5
|
zongertinib
Otros nombres:
|
|
Experimental: Phase Ia - Dose escalation part
Consecutive cohorts of patients treated with escalating doses of BI 1810631 monotherapy. |
zongertinib
Otros nombres:
|
|
Experimental: Phase Ib - Dose expansion part: Cohort 6
Cohort only in the United States of America (USA) |
zongertinib
Otros nombres:
|
|
Experimental: Phase Ib - Dose expansion part: Cohort 7
Cohort only in Japan |
zongertinib
Otros nombres:
|
|
Experimental: Phase Ib - Dose expansion part: Cohort 8
Cohort only in the United States of America (USA) |
zongertinib
Otros nombres:
|
|
Experimental: Phase Ib - Dose expansion part: Cohort 9
Cohort only in China |
zongertinib
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Fase Ia: número de pacientes con toxicidades limitantes de dosis (DLT) en el período de evaluación de MTD
Periodo de tiempo: Al final del Ciclo 1 (cada ciclo es de 21 días).
|
Al final del Ciclo 1 (cada ciclo es de 21 días).
|
|
|
Fase Ib: Cohorte 4: Respuesta objetiva según Evaluación de respuesta en neurooncología para metástasis cerebrales (RANO-BM) por revisión central independiente
Periodo de tiempo: Desde el inicio del tratamiento de prueba hasta el final del mes 12, hasta 12 meses.
|
Desde el inicio del tratamiento de prueba hasta el final del mes 12, hasta 12 meses.
|
|
|
Phase Ia: Maximum Tolerated Dose (MTD)
Periodo de tiempo: At the end of Cycle 1 (each cycle is 21 days).
|
Maximum tolerated dose is defined as the highest dose with less than 25% risk of the true Dose Limiting Toxicity (DLT) rate being equal to or above 33% during the MTD evaluation period in any studied regimen. |
At the end of Cycle 1 (each cycle is 21 days).
|
|
Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Objective response (OR) as assessed by central independent review
Periodo de tiempo: From the start of the trial treatment until end of month 12, up to 12 months.
|
OR is defined as best overall response of complete response (CR) or partial response (PR), where best overall response is determined according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1, from the first treatment administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anticancer therapy, loss to follow-up or withdrawal of consent. |
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
Phase Ib - Cohorts 3 (patients prior to CTP v8.0), 6, 7, 8, and 9: Objective response according to RECIST 1.1 by investigator assessment
Periodo de tiempo: From the start of the trial treatment until end of month 12, up to 12 months.
|
Clincal Trial Protocol version 8.0 = CTP v8.0 |
From the start of the trial treatment until end of month 12, up to 12 months.
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Fase Ia: número de pacientes que experimentaron DLT durante todo el período de tratamiento
Periodo de tiempo: Desde el inicio del tratamiento de prueba hasta el final del mes 8, hasta 8 meses.
|
Desde el inicio del tratamiento de prueba hasta el final del mes 8, hasta 8 meses.
|
|
|
Fase Ib - Cohorte 4: Duración de la respuesta objetiva (DoR) según RANO-BM por revisión independiente central
Periodo de tiempo: Desde el inicio del tratamiento de prueba hasta el final del mes 12, hasta 12 meses.
|
Desde el inicio del tratamiento de prueba hasta el final del mes 12, hasta 12 meses.
|
|
|
Fase Ib - Cohorte 4: Control de enfermedades (DC) según RANO-BM por revisión central independiente
Periodo de tiempo: Desde el inicio del tratamiento de prueba hasta el final del mes 12, hasta 12 meses.
|
Desde el inicio del tratamiento de prueba hasta el final del mes 12, hasta 12 meses.
|
|
|
Fase Ib - Cohorte 4: Supervivencia libre de progresión (PFS) según RANO-BM evaluada por una revisión central independiente
Periodo de tiempo: Desde el inicio del tratamiento de prueba hasta el final del mes 12, hasta 12 meses.
|
Desde el inicio del tratamiento de prueba hasta el final del mes 12, hasta 12 meses.
|
|
|
Fase Ib - Cohorte 4: O según RECIST 1.1 por revisión central independiente
Periodo de tiempo: Desde el inicio del tratamiento de prueba hasta el final del mes 12, hasta 12 meses.
|
Desde el inicio del tratamiento de prueba hasta el final del mes 12, hasta 12 meses.
|
|
|
Fase Ib - Cohorte 4: Duración de OR según RECIST 1.1 por revisión central independiente
Periodo de tiempo: Desde el inicio del tratamiento de prueba hasta el final del mes 12, hasta 12 meses.
|
Desde el inicio del tratamiento de prueba hasta el final del mes 12, hasta 12 meses.
|
|
|
Fase Ib - Cohorte 4: DC según RECIST 1.1 por revisión central independiente
Periodo de tiempo: Desde el inicio del tratamiento de prueba hasta el final del mes 12, hasta 12 meses.
|
Desde el inicio del tratamiento de prueba hasta el final del mes 12, hasta 12 meses.
|
|
|
Fase Ib - Todas las cohortes: número de pacientes que experimentaron DLT durante todo el período de tratamiento
Periodo de tiempo: Desde el inicio del tratamiento de prueba hasta el final del mes 12, hasta 12 meses.
|
Desde el inicio del tratamiento de prueba hasta el final del mes 12, hasta 12 meses.
|
|
|
Fase Ib: todas las cohortes: cambio desde el inicio hasta el día 1 del ciclo 5 en el puntaje del dominio de funcionamiento físico del cuestionario básico de calidad de vida de EORTC (EORTC QLQ-C30)
Periodo de tiempo: Línea de base y en el Día 1 del Ciclo 5 (cada ciclo es de 21 días).
|
Línea de base y en el Día 1 del Ciclo 5 (cada ciclo es de 21 días).
|
|
|
Fase Ib - Todas las cohortes: cambio desde el inicio hasta el día 1 del ciclo 5 en la puntuación total del Cuestionario de evaluación de síntomas de cáncer de pulmón de células no pequeñas (NSCLC-SAQ)
Periodo de tiempo: Línea de base y en el Día 1 del Ciclo 5 (cada ciclo es de 21 días).
|
Línea de base y en el Día 1 del Ciclo 5 (cada ciclo es de 21 días).
|
|
|
Fase Ib - Todas las cohortes: cambio desde el inicio hasta el día 1 del ciclo 5 en la puntuación de la lista de elementos 46 (IL46) de la EORTC
Periodo de tiempo: Línea de base y en el Día 1 del Ciclo 5 (cada ciclo es de 21 días).
|
Línea de base y en el Día 1 del Ciclo 5 (cada ciclo es de 21 días).
|
|
|
Fase Ia: concentración máxima medida de zongertinib en plasma (Cmax)
Periodo de tiempo: El día 1 y el día 15 del Ciclo 1 (cada ciclo es de 21 días).
|
El día 1 y el día 15 del Ciclo 1 (cada ciclo es de 21 días).
|
|
|
Fase Ia: Área bajo la curva de concentración-tiempo de zongertinib en plasma (AUC0-t2)
Periodo de tiempo: El día 1 y el día 15 del Ciclo 1 (cada ciclo es de 21 días).
|
El día 1 y el día 15 del Ciclo 1 (cada ciclo es de 21 días).
|
|
|
Fase Ib: todas las cohortes: supervivencia general (SG), definida como el tiempo desde la administración del primer tratamiento hasta la muerte por cualquier causa.
Periodo de tiempo: Desde el inicio del tratamiento de prueba hasta el final del mes 12, hasta 12 meses.
|
Desde el inicio del tratamiento de prueba hasta el final del mes 12, hasta 12 meses.
|
|
|
Fase IB - Cohorte 4: PFS según Recist 1.1 por Central Independent Review
Periodo de tiempo: Desde el comienzo del tratamiento del ensayo hasta el final del mes 12, hasta 12 meses.
|
Desde el comienzo del tratamiento del ensayo hasta el final del mes 12, hasta 12 meses.
|
|
|
Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Duration of objective response (DoR) according to RECIST 1.1
Periodo de tiempo: From the start of the trial treatment until end of month 12, up to 12 months.
|
DoR is defined as the time from first documented complete response (CR) or partial response (PR) until the earliest of disease progression or death among patients with objective response as assessed by central independent review. |
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Disease control (DC)
Periodo de tiempo: From the start of the trial treatment until end of month 12, up to 12 months.
|
DC is defined as best overall response of complete response (CR) or partial response (PR) or stable disease (SD) where best overall response is defined according to RECIST version 1.1 as assessed central independent review, from first treatment administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow-up or withdrawal of consent. |
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Progression-free survival (PFS)
Periodo de tiempo: From the start of the trial treatment until end of month 12, up to 12 months.
|
PFS is defined as the time from first treatment administration until tumor progression according to RECIST version 1.1 as assessed by central independent review, or death from any cause, whichever occurs earlier. |
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Objective response according to response assessment in RANO-BM criteria as assessed by central independent review for patients with central nervous system (CNS) lesions at baseline
Periodo de tiempo: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Disease control according to RANO-BM criteria as assessed by central independent review for patients with CNS lesions at baseline
Periodo de tiempo: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Objective response in CNS lesions according to RECIST 1.1 criteria as assessed by central independent review for patients with CNS lesions at baseline
Periodo de tiempo: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Disease control in CNS lesions according to RECIST 1.1 criteria as assessed by central independent review for patients with CNS lesions at baseline
Periodo de tiempo: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Duration of objective response according to RECIST 1.1 by investigator assessment
Periodo de tiempo: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Disease control according to RECIST 1.1 as assessed by the investigator
Periodo de tiempo: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Progression-free survival according to RECIST 1.1 as assessed by the investigator
Periodo de tiempo: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Objective response according to RANO-BM criteria as assessed by the investigator for patients with CNS lesions at baseline
Periodo de tiempo: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Disease control according to RANO-BM criteria as assessed by the investigator for patients with CNS lesions at baseline
Periodo de tiempo: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohort 4: DoR in CNS lesions according to RECIST 1.1 by central independent review
Periodo de tiempo: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohort 4: DC in CNS lesions according to RECIST 1.1 by central independent review
Periodo de tiempo: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohort 4: PFS in CNS lesions according to RECIST 1.1 as assessed by central independent review
Periodo de tiempo: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Heymach JV, Ruiter G, Ahn MJ, Girard N, Smit EF, Planchard D, Wu YL, Cho BC, Yamamoto N, Sabari JK, Zhao Y, Tu HY, Yoh K, Nadal E, Sadrolhefazi B, Rohrbacher M, von Wangenheim U, Eigenbrod-Giese S, Zugazagoitia J; Beamion LUNG-1 Investigators. Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2025 Jun 19;392(23):2321-2333. doi: 10.1056/NEJMoa2503704. Epub 2025 Apr 28.
- Heymach JV, Opdam F, Barve M, Tu HY, Wu YL, Berz D, Schroter L, Botilde Y, Sadrolhefazi B, Serra J, Yoh K, Yamamoto N. HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study. J Clin Oncol. 2025 Apr 10;43(11):1337-1347. doi: 10.1200/JCO-24-01727. Epub 2025 Mar 3.
- Heymach J, Opdam F, Barve M, Gibson N, Sadrolhefazi B, Serra J, Yamamoto N. A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations. Clin Lung Cancer. 2023 Mar;24(2):e65-e68. doi: 10.1016/j.cllc.2022.10.008. Epub 2022 Nov 11.
- Heymach JV, Yamamoto N, Girard N, Ruiter G, Smit EF, Planchard D, Nadal E, Wu YL, Zugazagoitia J, Tu HY, Baik CS, Yoh K, Soo RA, Zhao Y, Sabari JK, Wermke M, Scheffler M, Ahn MJ, Fernamberg K, Schroeter L, Sadrolhefazi B, Thamer C, Eigenbrod-Giese S, Popat S; Beamion LUNG-1 Investigators. First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2026 Apr 30;394(17):1675-1684. doi: 10.1056/NEJMoa2516969. Epub 2026 Apr 15.
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Neoplasias por sitio
- Neoplasias
- Enfermedades de las vías respiratorias
- Enfermedades pulmonares
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Procesos Neoplásicos
- Neoplasias Pulmonares
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Condiciones Patológicas, Signos y Síntomas
- Metástasis de neoplasias
- Carcinoma de pulmón de células no pequeñas
Otros números de identificación del estudio
Otros números de identificación del estudio
- 1479-0001
- 2020-004563-47 (Número EudraCT)
- 2024-511246-39-00 (Identificador de registro: CTIS (EU))
- U1111-1312-5969 (Identificador de registro: WHO International Clinical Trials Registry Platform (ICTRP))
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).
For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .